Admescope’s broad service portfolio encompasses all drug modalities—from small molecules and peptides to larger biologics—regardless of the project stage. In our last newsletter, we highlighted our comprehensive quantitative bioanalysis services. This time, we are focusing on a newer type of modality: oligonucleotides.
You might recall that some time ago we launched our services to cover also oligonucleotides, and the assays are tailored to address the unique challenges of oligonucleotide drug development and support you in obtaining the critical data needed for confident decision-making. It has been delightful to observe that since the launch of this new service type, we have collaborated on a high number of projects with our global customers on their oligonucleotide projects – so thank you for choosing us! – so thank you for choosing us!
Why would you choose to partner with Admescope? To support your projects, we offer expertise in evaluating metabolic stability, metabolite formation, plasma protein binding, and drug-drug interaction assessments. By leveraging our state-of-the-art analytical capabilities, we ensure accurate, high-quality data at every stage of the project. Our team understands the distinctive characteristics of oligonucleotides and takes these aspects in consideration while planning the experiments.
In vitro metabolism studies for oligonucleotides are performed using carefully selected enzymatic matrices such as hepatocyte systems, plasma, liver, and kidney fractions. These studies are adapted to account for the high stability of oligonucleotides, using optimized incubation times and cell-based models to generate reliable and meaningful results.
Plasma protein binding is assessed with precision using ultrafiltration techniques optimized specifically for oligonucleotides. This involves specialized preparation steps, including pre-washing with detergent solutions, to ensure accurate determination of this key parameter.
For preclinical in vivo DMPK studies, our comprehensive service package covers every stage, from conducting the in-life phase to advanced bioanalysis using LC/MS, ELISA, or qPCR. We process and report data thoroughly, delivering valuable insights into oligonucleotide pharmacokinetics and supporting the advancement of your development program.
At Admescope, we are committed to providing dependable, high-quality support for your oligonucleotide projects. Whether you are focused on in vitro metabolism or exploring preclinical in vivo pharmacokinetics, our team is here to deliver the data you need to move forward with confidence.
Exploring delivery options for your ASOs? Connect with our specialty lipid synthesis experts to discuss how we can support the development of a drug delivery system that meets your project’s needs.
Working with small molecules?
If you’re new to the world of oligonucleotides, we invite you to download our free e-book, “Preclinical Characterization of Biologics: Part 2.” It’s an excellent resource to help you get acquainted with this exciting field and its unique considerations.
And don’t forget to check our material bank on the website either, you can find e.g. a poster about the in vitro in vivo correlation of ASOs.
Contact us today to explore how we can support your project, no matter the drug modality you’re working on.
Summer’s here—but so are we!
As the holiday season kicks off and sunny distractions call, we’d like to remind you that our labs remain fully operational—rain or shine, heatwave or not.
Whether you’re facing a summer ADME-Tox screening bottleneck or need regulatory-compliant in vitro DDI assessments, our team is ready to support you. From absorption to excretion (and everything in between), we’re here to deliver expert ADME-Tox services all summer long.
Stay safe, enjoy the sunshine—and don’t hesitate to get in touch. We’re just a message away!
